Studies have demonstrated that smokers have lower levels of brain monoamine oxidase
(MAO) A and B activity and lower MAO-B platelet activity than non-smokers. Recent …

Prompted by the findings that smokers have lowered brain and blood platelet monoamine
oxidase-A and-B activities compared to non-smokers and that smokers have a lowered …

The potential neuroprotective properties of monoamine oxidase B (MAO-B) inhibitors have
been of interest in part because of the role that this enzyme plays in the bioactivation of the …

Epidemiological evidence suggests a lower incidence of Parkinson's disease in smokers
than in nonsmokers. This evidence, together with the lower levels of brain monoamine …

Current cigarette smokers have reduced monoamine oxidase (MAO) and there is evidence
that this is a pharmacological effect of tobacco smoke exposure rather than a biological …

Monoamine oxidase (MAO) is a mitochondrial outer-membrane flavoenzyme involved in
brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines …

We measured the concentration of brain monoamine oxidase B (MAO B; EC 1.4. 3.4) in 8
smokers and compared it with that in 8 non-smokers and in 4 former smokers using positron …

Recent positron emission tomography imaging studies have demonstrated a significant
decrease in both monoamine oxidase A and B (MAO-A and MAO-B) activities in the brains of …

Although nicotine has been identified as the main ingredient in tobacco responsible for
aspects of the tobacco dependence syndrome, not all of the psychopharmacological effects …

Background: There is a hypothesis that substances present in, or derived from, tobacco
smoke inhibit monoamine oxidase (MAO) in the brains of smokers, reducing the degradation …